ArticleMicrobial cell factories2026
Metabolic engineering of Streptomyces albulus for de novo serotonin production.
Article in Microbial cell factories, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundSerotonin (5-hydroxytryptamine, 5-HT) is a pivotal neurotransmitter with broad clinical relevance. However, its industrial-scale microbial production remains a significant challenge. In this study, we engineered Streptomyces albulus to develop an efficient enzymatic cascade for the scalable and high-yield biosynthesis of 5-HT.
resultsTo enhance 5-HT production, we first overexpressed the native 5-hydroxytryptophan decarboxylase (5-OHTDC) in S. albulus, which strengthened the final decarboxylation step. Using 5-hydroxytryptophan as the substrate, this modification achieved a 5-HT titer of 6.87 g/L. We then introduced Escherichia coli L-tryptophan permease (Mtr) to improve cellular uptake of L-tryptophan, along with Actinomadura luzonensis tryptophan 5-hydroxylase (Luz15) to catalyze the hydroxylation of L-tryptophan. This triple-enzyme expression system (5-OHTDC/Mtr/Luz15) enabled the direct conversion of L-tryptophan to 5-HT, yielding 3.46 g/L. Leveraging the innate L-tryptophan biosynthesis capability of S. albulus, we pursued direct fermentative production from low-cost carbon sources. Mannitol was identified as the optimal substrate, supporting a maximum 5-HT titer of 6.54 g/L in fed-batch fermentation. Finally, implementing an L-tryptophan feeding strategy further boosted the final 5-HT titer to 12.0 g/L.
conclusionsThis work establishes S. albulus as an efficient microbial platform for high-level 5-HT production. The engineered strain and optimized fermentation process demonstrate strong potential for industrial application and provide a versatile chassis for synthesizing diverse tryptophan-derived bioactive compounds.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.